The NADIMII phase 2 trial aimed to analyze F. prausnitzii’s potential as a cancer preventative in patients with NSCLC. The results revealed that the F. prausnitzii presence was associated with improved survival in patients with NSCLC. Aprominent member of the gut microbiota, Faecalibacterium prausnitzii is known for its significant contribution to butyrate production […]...
ELCC 2024
Coverage of European Lung Cancer Congress 2024
Mar 20
-Mar 23, 2024